Cambrex Appoints Leaders for Two New Executive Roles


East Rutherford, NJ – October 16, 2023 – Cambrex today announced that Claudio Russolo has been named Chief Operating Officer, Drug Substance. Additionally, Matt Bio has been appointed to the new role of Chief Scientific Officer (CSO) while maintaining his role as President, Snapdragon Chemistry.

Claudio Russolo joined Cambrex in 2002 and previously served as President of the Specialty Generics Business Unit, where he has been instrumental in the growth of the business. In his new role, Claudio will oversee the global drug substance and specialty generics business unit.

Matt joined Cambrex in 2023 as President, Snapdragon Chemistry, overseeing day-to-day operations and integration activities. Since the acquisition of Snapdragon Chemistry, Matt has been an integral part of the leadership team. In his new CSO role, Matt will guide Cambrex’s scientific and technical strategy and build on our position as a leader for increasingly complex synthetic APIs and new therapeutic modalities.

We are proud to announce the well-deserved promotions of these two accomplished leaders from within our organization and look forward to the innovative and transformative impact that they will make in their expanded roles.

About Cambrex
Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance, drug product, and analytical services across the entire drug lifecycle. With over 40 years of experience and a growing team of over 2,400 experts servicing global clients from North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and finished dosage form development and manufacturing.

Cambrex offers a range of specialized drug substance technologies and capabilities, including biocatalysis, continuous flow, controlled substances, solid-state science, material characterization, stability storage, and highly potent APIs. In addition, Cambrex can support conventional dosage forms, including oral solids, semi-solids, and liquids, and has the expertise to manufacture specialty dosage forms such as modified-release, fixed-dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile, and non-sterile ointments.